Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
Jaipur, January 04, 2024. Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, has launched a biosimilar of the popular10,11 anti-diabetic drug, Liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit™ following the approval from the Drug Controller General of India (DCGI). Priced at around INR 100 for…